Indian stocks: Visit www.stage2stocks.com →

ALX Oncology Holdings Inc.

Stage 4 · Declining · week 3

As of Oct 22, 2026, ALX Oncology Holdings is in Stage 4, the downtrend phase, now in week 3 (since Oct 5, 2026). It closed at $1.19, 54.2% below its 52-week high and below its 200-day average, which is falling.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. More about the company

$1.19
+6.25% today
$165M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ALXO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 19w
S4 27w
S4 24w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 8w → S1 3w → S2 19w → S3 7w → S2 4w → S3 4w → S4 27w → S1 5w → S4 24w → S1 8w → S2 12w → S3 7w → S2 12w → S3 10w → S2 11w → S3 1w → S4 3w current
Total tracked: 166 weeks across 17 stage runs.

ALXO among Biotechnology271st of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…271ALXOStage 4 · wk 335−19.0%
vs 52W High
-54.2%
$0.90 lo$2.60 hi
54.2% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 3
1w13w26w
Week 3, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-34.9%
200 DMA: $1.83 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.49x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-19.0%
3M
-41.4%
6M
-25.2%
YTD
+3.5%
1Y
-27.4%
Scan Membership
Breakout Watch
Latest: 2024-05-08
3 appearances in last 60 days. First seen: 2021-09-29.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 3 · Vol 0.49x
2026-10-21S4
Wk 3 · Vol 0.72x
2026-10-20S4
Wk 3 · Vol 0.75x
2026-10-19S4
Wk 3 · Vol 0.77x
2026-10-16S4
Wk 2 · Vol 1.90x
2026-10-15S4
Wk 2 · Vol 3.05x
2026-10-14S4
Wk 2 · Vol 2.19x
2026-10-13S4
Wk 2 · Vol 0.86x
2026-10-12S4
Wk 2 · Vol 0.77x
2026-10-09S4
Wk 1 · Vol 1.07x
2026-10-08S4
Wk 1 · Vol 1.62x
2026-10-07S4
Wk 1 · Vol 0.69x
Moving averages & range
50 DMA
$1.61
200 DMA
$1.83
52W High
$2.60
52W Low
$0.90
5D Low
$1.06
Resistance levels (recent highs)
20d High
$1.39
60d High
$2.11
120d High
$2.36
250d High
$2.60
Next resistance
+16.8%
to 20d High
ROE
-80.6%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 1.2

ALX Oncology Holdings: quick answers

What stage is ALX Oncology Holdings in?

As of Oct 22, 2026, ALX Oncology Holdings (ALXO) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 5, 2026 and is in week 3. What the four stages mean

Is ALX Oncology Holdings in an uptrend?

No. ALX Oncology Holdings is in a Stage 4 downtrend. It trades 34.9% below its 200-day average, which is falling.

How far is ALX Oncology Holdings from its 52-week high?

ALX Oncology Holdings closed at $1.19 on Oct 22, 2026, 54.2% below its 52-week high of $2.60. Its 52-week low is $0.90.

How has ALX Oncology Holdings performed over the past year?

As of Oct 22, 2026, ALX Oncology Holdings is down 27.4% over the past year and up 3.5% so far in 2026.

Which sector and industry is ALX Oncology Holdings in?

ALX Oncology Holdings is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.